Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol

INTRODUCTION: Epilepsy is one of the most common neurological conditions worldwide. Despite many antiseizure medications (ASMs) being available, up to one-third of patients do not achieve seizure control. Preclinical studies have shown treatment with sodium selenate to have a disease-modifying effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Vivash, Lucy, Johns, Hannah, Churilov, Leonid, MacPhail, Sara, Casillas-Espinosa, Pablo, Malpas, Charles, Shultz, Sandy R, Tailby, Chris, Wijayath, Manori, Reutens, David, Gillinder, Lisa, Perucca, Piero, Carney, Patrick, Nicolo, John-Paul, Lawn, Nicholas, Kwan, Patrick, Velakoulis, Dennis, Hovens, Christopher M, O’Brien, Terence J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619053/
https://www.ncbi.nlm.nih.gov/pubmed/37890967
http://dx.doi.org/10.1136/bmjopen-2023-075888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619053/
https://www.ncbi.nlm.nih.gov/pubmed/37890967
http://dx.doi.org/10.1136/bmjopen-2023-075888

Ejemplares similares